Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients

BACKGROUND: Following approval of imatinib, a breakthrough tyrosine kinase inhibitor (TKI), survival significantly improved by more than 20% since 2001 among treated chronic myelogenous leukemia (CML) patients. Subsequently, more expensive second-generation TKIs with varying selectivity profiles hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Donna R, Enewold, Lindsey, Barrett, Michael J, Banegas, Matthew P, Filipski, Kelly K, Freedman, Andrew N, Lam, Clara K, Mariotto, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391029/
https://www.ncbi.nlm.nih.gov/pubmed/33251998
http://dx.doi.org/10.18553/jmcp.2020.26.12.1494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391029/
https://www.ncbi.nlm.nih.gov/pubmed/33251998
http://dx.doi.org/10.18553/jmcp.2020.26.12.1494

Ejemplares similares